10-Q: Avalon GloboCare Reports Q1 2026 Financials, Focuses on AI and KetoAir

Avalon GloboCare Corp. filed its Q1 2026 Form 10-Q, detailing a net loss of $4.48 million and highlighting strategic shifts towards AI-driven content technology and the KetoAir breathalyzer.

Summary

• Avalon GloboCare Corp. reported a net loss of $4,479,695 for the three months ended March 31, 2026, compared to a net loss of $2,482,111 for the same period in 2025.
• The company's strategic focus has shifted towards AI-driven systems, including automated video production and small business marketing automation, and the commercialization of the KetoAir breathalyzer device.
• Operations related to laboratory services have ceased, and the real estate segment (Avalon RT 9) was sold in February 2026.
• The company's cash balance at March 31, 2026, was $775,995, and management has expressed substantial doubt about its ability to continue as a going concern, planning to raise additional capital through equity or debt.
• Total operating expenses increased to $2,721,126 in Q1 2026 from $2,178,100 in Q1 2025, largely due to increased advertising and marketing expenses and amortization of intangible assets.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss, substantial doubt about going concern, and significant operating expenses, despite strategic shifts and a recent capital raise.

Positives

• Increased cash balance to $775,995 as of March 31, 2026, from $109,091 as of December 31, 2025.
• Significant reduction in current liabilities by $9,702,541, leading to a decreased working capital deficit.
• Successful sale of the real estate subsidiary (Avalon RT 9) for $9.0 million, which was a related party transaction.
• Progress in developing AI systems, including automated video generation and small business marketing automation.
• Continued marketing and distribution of the FDA-registered KetoAir breathalyzer device.

Negatives

• Net loss increased to $4,479,695 in Q1 2026 from $2,482,111 in Q1 2025.
• Loss from operations increased by 52.4% to $2,721,126 in Q1 2026.
• Substantial doubt about the company's ability to continue as a going concern due to recurring net losses and negative cash flow from operations.
• Increased advertising and marketing expenses by 194.9%.
• Significant increase in amortization expense due to acquired intangible assets.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital, implementing its business plan, and generating sufficient revenues.
• There is no assurance that future financing will be available on satisfactory terms, or at all.
• The trading price of common stock and downturns in equity/debt markets could make obtaining financing more difficult.
• The company faces risks related to the commercialization of its product candidates and the development of products before competitors.
• A decline in economic conditions, including inflation and tariffs, could impact results.

Future Outlook

The company plans to raise additional capital through equity or debt to fund future obligations and implement its business plan. Future operations are dependent on securing this financing. The company expects cash used in operating activities to increase in the next 12 months due to product development, commercialization, and increased public relations/sales promotions.

Management Comments

• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company plans on raising capital through the sale of equity to implement its business plan, but there is no assurance these plans will be realized.
• Management expects advertising and marketing expenses to remain at current levels with minimal increase.
• Management expects professional fees to decrease in the near future.
• Management expects compensation and related benefits to remain at current levels with minimal decrease.

Industry Context

StockSavvy.ai notes that Avalon GloboCare's strategic pivot towards AI-driven content technology and health diagnostics (KetoAir) reflects broader industry trends of leveraging AI for content creation and personalized health solutions. However, the company's significant net loss and going concern warning highlight the challenges of scaling in these competitive and capital-intensive sectors.

Comparison to Industry Standards

• The company's net loss of $4.48 million for the quarter is substantial relative to its current market capitalization and revenue generation capabilities, indicating a high burn rate typical of early-stage technology and biotech companies, but requiring significant future funding.
• The increase in advertising and marketing expenses by 194.9% suggests an aggressive push for market penetration for its products like KetoAir, which is a common strategy in the consumer health device market, though its effectiveness needs to be monitored against revenue growth.
• The significant amortization of intangible assets ($563,000) is a direct result of the recent acquisition of RPM Interactive, Inc., a common practice in the tech and AI sectors to account for acquired intellectual property and technology.

Legal Proceedings

• The company is involved in a lawsuit filed by Research Institute at Nationwide Children's Hospital concerning misappropriation of trade secrets, with a settlement agreement requiring payments based on future pre-tax profits.

Related Party Transactions

• The company sold its subsidiary, Avalon RT 9, to Wenzhao Lu, the Chairman of the Board, for $9.0 million.
• An advance of $3,158,078 from Wenzhao Lu was applied to the proceeds of the Avalon RT 9 sale.
• The company recorded $1,861,266 to additional paid-in capital related to the sale of Avalon RT 9, representing proceeds in excess of its carrying value.
• Consulting services were provided by Wilbert Tauzin, a former director, and his son.
• An unpaid acquisition consideration of $100,000 is payable to Dr. Yu Zhou, a former director and officer, related to the Genexosome subsidiary.

Stakeholder Impact

• Shareholders may experience dilution due to planned future equity issuances for capital raising.
• Creditors and lenders face increased risk given the company's going concern status and reliance on future financing.
• Employees may be impacted by the company's financial instability and potential need for further cost-saving measures.
• Suppliers may face extended payment terms or increased scrutiny due to the company's liquidity concerns.

Next Steps

• Continue advancing patent applications related to QTY code protein design and CAR-T cellular therapy.
• Commercialize and develop the KetoAir breathalyzer system, targeting diabetes and obesity markets.
• Advance next-generation Agentic AI systems, including automated video generation and small business marketing automation solutions.
• Raise additional capital through equity or debt to fund operations and future obligations.
• Obtain shareholder approval for the issuance of warrants and shares upon exercise.

Key Dates

Recommendation

The company is in a transitional phase, shifting focus to AI and health tech while facing significant financial challenges and a going concern warning. While the strategic direction is promising, the immediate financial instability and need for further capital make it a hold. Investors should monitor future financing efforts and the execution of the new business strategy.

Keywords

Avalon GloboCare, Form 10-Q, Quarterly Report, AI, KetoAir, Breathalyzer, Net Loss, Going Concern, Financing, Equity, Debt, Amortization, Operating Expenses, Discontinued Operations, Related Party Transaction